Molecular Brain | 卷:14 |
Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson’s disease model | |
Patricia Spilman1  Samantha Focht1  Jesus Campagna1  Chris Jean Elias1  Whitaker Cohn1  Varghese John1  Asa Hatami1  Chunni Zhu1  Sujyoti Chandra1  Michael Jun1  Tina Bilousova1  Mikhail Melnik1  Karen Hoppens Gylys2  | |
[1] Drug Discovery Lab, Department of Neurology, University of California; | |
[2] School of Nursing, University of California; | |
关键词: Parkinson’s disease; Alpha-synuclein; Extracellular vesicles; Exosomes; Neutral sphingomyelinase-2; | |
DOI : 10.1186/s13041-021-00776-9 | |
来源: DOAJ |
【 摘 要 】
Abstract Aim We have previously reported that cambinol (DDL-112), a known inhibitor of neutral sphingomyelinase-2 (nSMase2), suppressed extracellular vesicle (EV)/exosome production in vitro in a cell model and reduced tau seed propagation. The enzyme nSMase2 is involved in the production of exosomes carrying proteopathic seeds and could contribute to cell-to-cell transmission of pathological protein aggregates implicated in neurodegenerative diseases such as Parkinson’s disease (PD). Here, we performed in vivo studies to determine if DDL-112 can reduce brain EV/exosome production and proteopathic alpha synuclein (αSyn) spread in a PD mouse model. Methods The acute effects of single-dose treatment with DDL-112 on interleukin-1β-induced extracellular vesicle (EV) release in brain tissue of Thy1-αSyn PD model mice and chronic effects of 5 week DDL-112 treatment on behavioral/motor function and proteinase K-resistant αSyn aggregates in the PD model were determined. Results/discussion In the acute study, pre-treatment with DDL-112 reduced EV/exosome biogenesis and in the chronic study, treatment with DDL-112 was associated with a reduction in αSyn aggregates in the substantia nigra and improvement in motor function. Inhibition of nSMase2 thus offers a new approach to therapeutic development for neurodegenerative diseases with the potential to reduce the spread of disease-specific proteopathic proteins.
【 授权许可】
Unknown